Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

NIH 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 4Breast 4Thoracic 3Tumor-Agnostic 2Sarcoma 2Genitourinary 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Pancreatic Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × saracatinib × Gastrointestinal × Clear all
NCT00265876 2023-08-04

AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Canadian Cancer Trials Group

Phase 1/2 Completed
34 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00735917 2019-04-02

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 7 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00607594 2018-08-23

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 11 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡